3.90
+0.17(+4.56%)
Currency In USD
| Previous Close | 3.73 |
| Open | 3.72 |
| Day High | 3.9 |
| Day Low | 3.68 |
| 52-Week High | 8.28 |
| 52-Week Low | 2.65 |
| Volume | 321,980 |
| Average Volume | 774,050 |
| Market Cap | 216.33M |
| PE | -2.1 |
| EPS | -1.86 |
| Moving Average 50 Days | 3.26 |
| Moving Average 200 Days | 4.35 |
| Change | 0.17 |
If you invested $1000 in Voyager Therapeutics, Inc. (VYGR) since IPO date, it would be worth $209.1 as of August 18, 2025 at a share price of $3.712. Whereas If you bought $1000 worth of Voyager Therapeutics, Inc. (VYGR) shares 5 years ago, it would be worth $316.95 as of August 18, 2025 at a share price of $3.712.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
GlobeNewswire Inc.
Jul 16, 2025 11:00 AM GMT
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now include
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Exec
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
GlobeNewswire Inc.
May 15, 2025 11:00 AM GMT
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demon